NCT06925360

IVIG Trial for the Treatment of Bronchopulmonary Dysplasia

The Efficacy of Intravenous Immunoglobulin for the Treatment of Bronchopulmonary Dysplasia

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: International Peace Maternity and Child Health Hospital · Academic / Other
• Sex: All
• Age: 10 Weeks
• Healthy volunteers: Accepted

Summary

It is intended to examine the efficacy and safety of intravenous immunoglobulin(IVIG) for the bronchopulmonary dysplasia in preterms. Participants will received continuous infusion IVIG 1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable if necessary.

Conditions

• Bronchopulmonary Dysplasia

Interventions

Type	Name	Description
DRUG	intravenous immunoglobulin	1 g/kg/day for the first 2 days, 0.5 g/kg/day for next 3 days (total does 3.5 g/kg), repeatable if necessary.

Timeline

• Start date: 2025-04-12
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2025-04-13
• Last updated: 2026-04-01

Locations

1 site across 1 country: China